Ranibizumab and bevacizumab show equivalent effects on visual acuity in patients with neovascular AMD
June 1, 2011
Two of the most commonly used treatments for neovascular age-related macular degeneration, ranibizumab, approved by FDA in 2006, and the other commonly used 'off-label', bevacizumab, resulted in similar improvements in visual acuity, according to results of a new trial.